HROW•benzinga•
Melt Pharmaceuticals Announced Positive Topline Results Of Its Pivotal Phase 3 Study Evaluating The Safety And Efficacy Of Its Lead Product Candidate, Melt‑300, A Non-iv, Non-opioid Tablet For Procedural Sedation During Cataract Surge
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga